Labcorp’s $872 Million Bet: The Bigger Story Behind the BioReference Deal

An acquisition involving a prostate cancer blood test, a shrinking laboratory business, and two companies pursuing very different futures reveals where the economics of American diagnostics may be heading.

MacroHint | October 19, 2026

There is a peculiar feature of the medical testing business: the company that develops an important diagnostic is not necessarily the company best positioned to make money from it.

Developing a useful test requires scientific expertise, clinical validation, regulatory work, and years of investment. Making that test commercially successful requires something else entirely: relationships with physicians, contracts with insurers, convenient collection locations, reliable logistics, and enough testing volume to make the economics work.

Labcorp’s latest acquisition brings those two sides of the industry together.

On October 15, the North Carolina-based laboratory giant announced an agreement to acquire selected assets of BioReference Health, a subsidiary of OPKO Health, for $722 million in cash, with the possibility of another $150 million in performance-based payments.

The headline figure is $872 million. But the most revealing part of the agreement may be the relatively small business at the center of those additional payments: a blood test designed to help physicians assess the risk of aggressive prostate cancer.

The transaction is also the latest chapter in a relationship that has seen Labcorp steadily acquire portions of BioReference over the past two years.

For Labcorp, the attraction is scale. For OPKO, it is the opportunity to leave much of the laboratory business behind.

And for investors, the central question is whether both companies can become more valuable by separating assets that once belonged under the same corporate roof.

A $722 Million Purchase With a $150 Million Question Mark

The structure of the agreement deserves attention.

Labcorp will pay $722 million in cash at closing, subject to adjustments based on the acquired business’s revenue at that time. OPKO could receive another $150 million over a period of up to ten years, depending on the revenue generated by the 4Kscore prostate cancer test.

The distinction is important. The $872 million figure represents the maximum announced consideration before any closing adjustment, not a guaranteed payment.

Labcorp expects the acquired operations to generate approximately $250 million in revenue during their first year under its ownership.

At the initial $722 million purchase price, that works out to roughly 2.9 times expected annual revenue. Including the full potential earnout would bring the figure to approximately 3.5 times.

Those multiples are not inherently cheap or expensive. Their significance depends on how much profit the acquired business can produce, the capital required to maintain it, and how successfully Labcorp can integrate the operations.

Revenue is only the beginning of the valuation exercise.

Consider two laboratory businesses generating the same $250 million in annual sales. One operates at a 10% EBITDA margin, producing $25 million in annual EBITDA. The other achieves a 20% margin, producing $50 million.

At a $722 million acquisition price, those hypothetical outcomes imply purchase-price-to-EBITDA ratios of approximately 28.9 and 14.4 times, respectively.

Neither margin is a disclosed forecast for this acquisition. The illustration simply demonstrates how dramatically profitability changes the economics of an otherwise identical revenue stream.

Labcorp has not provided enough transaction-specific profitability information to conclude definitively whether the acquisition is attractively priced.

What it has disclosed is a revenue forecast, a purchase price, and an unusual degree of attention to one specialized test.

That is where the story becomes more interesting.

Why a Prostate Cancer Test Could Matter So Much

Prostate cancer screening presents physicians with a difficult problem.

A patient may have an elevated prostate-specific antigen, or PSA, reading without having aggressive cancer. PSA levels can rise for reasons other than malignancy, including benign prostate enlargement and inflammation.

Yet ignoring an abnormal result can also carry serious consequences.

A prostate biopsy can provide more definitive information, but it is invasive, can cause complications, and may detect cancers that would never have become clinically significant during a patient’s lifetime.

The challenge is deciding who genuinely needs further investigation.

BioReference’s 4Kscore test is designed to help with that decision.

The FDA-approved blood test measures four prostate-related proteins and combines the results with clinical information to estimate the likelihood of finding clinically significant prostate cancer.

It does not diagnose cancer. It does not eliminate the need for biopsies. Instead, it provides additional information that can help physicians and patients weigh the benefits and risks of further testing.

That distinction matters medically, and it matters commercially.

A test that can help physicians make better decisions before an invasive procedure addresses a real clinical need. But scientific usefulness does not automatically translate into widespread adoption.

Physicians must know about the test, understand when to use it, trust the supporting evidence, and have a practical way to order it. Patients need access to sample collection. Insurers must decide whether and under what circumstances they will pay for it.

These barriers can limit the growth of a specialized diagnostic even after regulatory approval.

Labcorp may be unusually well positioned to address several of them.

The company operates an extensive national laboratory infrastructure, with established physician relationships, collection networks, and experience managing complex reimbursement arrangements.

It reported performing more than 750 million tests worldwide and employing nearly 71,000 people in its October announcement.

The opportunity is to bring 4Kscore into a much larger commercial system.

And there is already a measurable starting point.

According to Reuters, 4Kscore generated $27.1 million in revenue in 2025.

That is meaningful business, but modest relative to Labcorp’s scale. The test’s 2025 revenue represented only about 11% of the $250 million in first-year revenue Labcorp expects from the entire acquired portfolio, although the figures refer to different periods and should not be treated as a precise post-acquisition revenue breakdown.

The investment thesis is not that 4Kscore is already a massive franchise.

It is that a useful, established diagnostic might become a substantially larger one when distributed through a national laboratory network.

That possibility is attractive. It is also uncertain.

The Most Revealing Detail Is the Earnout

The $150 million contingent payment is more than a technical provision in the acquisition agreement.

It offers a clue about how the companies have chosen to divide the risks and rewards of 4Kscore’s future.

An earnout allows a buyer to defer part of the consideration until an acquired business achieves specified performance measures. In this case, the additional payments depend on 4Kscore revenue generated after the acquisition.

For Labcorp, the arrangement limits how much it must pay upfront for commercial growth that has not yet occurred.

For OPKO, it preserves a degree of participation in the test’s future success even after ownership changes hands.

There is an interesting tension here.

OPKO developed and commercialized 4Kscore within BioReference, but the agreement effectively acknowledges that the test’s future commercial performance may be different under Labcorp’s ownership.

If national distribution significantly increases physician adoption, OPKO can benefit through the earnout. If growth disappoints, Labcorp avoids paying the entire headline price.

The precise payment thresholds are important, and the public summary of the agreement does not establish a simple formula allowing investors to calculate how much additional revenue would trigger the full $150 million.

Still, the economic logic is clear.

The companies have separated the value of the existing operations from some of the value that might be created through future commercialization.

That is a sophisticated way to address a familiar acquisition problem: the buyer and seller may agree on what a business is worth today while disagreeing about what it could become tomorrow.

BioReference Has Been Getting Smaller for a Reason

This is not the first time Labcorp has purchased assets from OPKO.

In September 2024, Labcorp acquired selected BioReference laboratory operations outside New York and New Jersey for approximately $237.5 million.

In September 2025, it completed another transaction involving BioReference’s oncology and related clinical testing businesses. That acquisition carried $192.5 million in upfront consideration and up to $32.5 million in additional performance-based payments.

The latest agreement is considerably larger.

Taken together, the three transactions carry approximately $1.15 billion in stated upfront consideration and roughly $1.33 billion in maximum announced consideration, before accounting for closing adjustments and whether contingent payments are ultimately earned.

Those figures should not be confused with proceeds already collected. The latest deal has not closed, and some payments across the transactions are conditional.

Nevertheless, the cumulative scale is striking.

OPKO has been dismantling significant portions of a laboratory business that once represented an important part of its corporate identity.

Why sell in pieces rather than all at once?

There is no single publicly established answer. But successive asset sales can allow a company to match different businesses with buyers that value them more highly, while preserving operations it is not yet ready to divest.

The strategy can also provide time to reorganize a remaining business between transactions.

The latest agreement suggests that OPKO’s strategic destination is now clearer than it was two years ago.

The company is increasingly emphasizing biopharmaceutical development rather than the ownership of a broad clinical laboratory network.

For Labcorp, the pattern has produced a series of acquisitions that extend its capabilities without requiring it to purchase every BioReference asset in a single transaction.

The relationship illustrates a broader principle of corporate finance: an asset’s value depends partly on who owns it.

A laboratory business may have one level of profitability as part of a smaller organization and a different level when integrated into a national network.

The physical equipment, clinical expertise, and customer relationships may be largely the same. The economics surrounding them can change considerably.

Why Size Matters in Medical Testing

Laboratory diagnostics is not an ordinary service business.

A medical practice cannot simply purchase a testing machine and reproduce the full capabilities of a national reference laboratory. Reliable diagnostic testing requires trained personnel, quality controls, specialized equipment, regulatory compliance, sample transportation, information systems, and arrangements for billing and reimbursement.

Many of those activities involve substantial fixed costs.

That creates an advantage for operators that can process large numbers of tests efficiently.

Suppose two laboratories each incur $10 million in annual fixed operating costs. One processes one million tests, while the other processes five million.

The first must spread those fixed costs across its smaller volume, equivalent to $10 per test. The second spreads the same costs across five times as many tests, equivalent to $2 per test.

Real laboratory economics are much more complicated, and the larger laboratory would not necessarily have identical fixed costs. But the example captures the fundamental attraction of scale.

Greater volume can reduce unit costs, particularly when additional tests can be processed using existing capacity.

Scale can also improve purchasing efficiency, support investments in automation, and make it easier to maintain specialized testing capabilities that would be uneconomic at smaller volumes.

The benefits are not unlimited.

Specimens still need to be transported. Collection sites require staff and rent. Laboratories must maintain turnaround times, accuracy, and service quality. Some tests require specialized workflows that cannot simply be absorbed into existing facilities.

Nor does consolidation guarantee better prices for patients or insurers.

But the possibility of combining additional testing volume with an established infrastructure helps explain why Labcorp continues acquiring laboratory assets.

The company is not merely accumulating revenue. It is attempting to improve the productivity and reach of an existing network.

The Less Obvious Asset: Physician Relationships

One of the most valuable things Labcorp is buying may never appear as a separate line item in the announcement.

It is access to established physician and customer relationships.

Laboratory testing depends heavily on habitual ordering behavior. Physicians and medical practices often develop established workflows with particular providers, from electronic ordering and specimen collection to results reporting.

Changing those workflows can be inconvenient, even when an alternative laboratory offers similar services.

A business that already serves physicians therefore possesses a form of commercial infrastructure that can be difficult to build from scratch.

The acquisition includes operations in clinical testing, women’s health, urology, and correctional healthcare, along with more than 80 patient service centers.

Those assets provide Labcorp with additional points of contact across the healthcare system.

For 4Kscore, the urology relationships may be particularly relevant.

The commercial value of a specialized prostate cancer test depends on reaching clinicians who evaluate patients with elevated PSA results and other risk factors.

Existing relationships with those clinicians could reduce some of the friction involved in expanding adoption.

But Labcorp must also retain those relationships after the acquisition.

An integration that disrupts service, changes ordering procedures, or creates billing problems could undermine the very customer base the company is paying to acquire.

This is why laboratory acquisitions are operationally demanding. A customer relationship has value only if it survives the transition.

OPKO Is Trading One Kind of Risk for Another

The sale looks different from OPKO’s side.

Laboratory testing can be operationally demanding and capital-intensive, but it also generates revenue from recurring clinical activity.

Biopharmaceutical development offers a different financial profile.

Successful products can generate substantial returns, particularly when they address important medical needs and benefit from intellectual property protection. But drug development also involves lengthy clinical programs, regulatory uncertainty, substantial research expenditure, and the possibility that promising treatments never reach commercial success.

By selling significant laboratory operations, OPKO may simplify its organization and strengthen its balance sheet.

It also becomes more exposed to the performance of its remaining pharmaceutical products, development programs, partnerships, and investments.

That trade-off deserves scrutiny.

OPKO’s portfolio includes Rayaldee, an FDA-approved treatment used in certain adults with chronic kidney disease and secondary hyperparathyroidism, alongside broader biopharmaceutical activities.

The proceeds from the Labcorp agreement could give management additional resources to support that portfolio.

But the amount ultimately available for investment will depend on closing adjustments, transaction expenses, taxes, liabilities, and other uses of cash.

More importantly, a stronger balance sheet does not guarantee a successful pharmaceutical strategy.

The sale can create financial flexibility. It cannot create clinical success.

For OPKO investors, the question is not simply whether the company receives hundreds of millions of dollars.

It is whether management can deploy that capital more effectively than the assets being sold would have generated value under continued ownership.

There is also an important distinction between accounting gains and lasting economic improvement.

A company may recognize a substantial gain from selling a business without improving the profitability of its remaining operations.

The transaction could make OPKO financially stronger while leaving its future earnings more dependent on a narrower range of outcomes.

That may ultimately be the right trade. It is not a risk-free one.

Wall Street Is Looking Beyond the Headline

The announcement initially drew a sharp reaction in OPKO shares, which rose approximately 20% in premarket trading on October 15, according to Reuters.

The response was understandable. A large asset sale can cause investors to reassess the value of a company’s remaining operations, especially when the consideration is substantial relative to the scale of the seller.

But a premarket rally is a snapshot of investor expectations, not proof that the transaction will create lasting shareholder value.

The deal has also attracted attention from healthcare analysts for reasons beyond its size.

Evercore ISI analysts identified the acquisition as consistent with Labcorp’s emphasis on higher-growth specialty testing. They also pointed to the opportunity to improve the economics of BioReference’s regional operations through Labcorp’s existing infrastructure.

William Blair analysts highlighted 4Kscore as a particularly interesting asset, given the potential for broader clinical adoption.

Those observations reinforce the central commercial argument.

The value of the acquisition may depend less on simply preserving the revenue of the purchased operations and more on what Labcorp can do with those operations after integration.

The distinction is essential.

Buying $250 million in annual revenue is one thing. Increasing the profitability of that revenue while expanding a differentiated diagnostic franchise is another.

The latter would make the transaction considerably more compelling.

An Antitrust Question Worth Watching

The acquisition is not yet complete.

According to OPKO’s October 15 SEC filing, the agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino antitrust process.

The filing identifies April 14, 2027, as a date after which the parties may have certain termination rights if the transaction has not closed, subject to possible extension by mutual agreement.

It also establishes a $28.88 million termination fee payable by Labcorp under specified circumstances involving failure to obtain required regulatory approvals.

That provision does not establish that regulators are likely to challenge the acquisition.

It does, however, confirm that regulatory risk is an explicitly addressed part of the transaction.

The competition question is not simply whether Labcorp is a large company. Regulators may examine the particular markets in which the acquired operations compete, the alternatives available to physicians and patients, and the potential effects on pricing and service.

A national laboratory market can contain distinct local and specialty markets with different competitive conditions.

That makes the transaction more nuanced than a simple comparison of the companies’ national market shares.

Until the required approvals are obtained and the deal closes, the two companies will continue operating independently.

The Next Earnings Reports Will Be More Interesting Than the Announcement

Labcorp is scheduled to report third-quarter 2026 financial results on October 28.

Because the acquisition remains pending, those results will not show the financial contribution of the BioReference assets being purchased.

They can, however, provide useful context about Labcorp’s existing operating performance, margins, cash generation, and management’s acquisition priorities.

The company’s outlook for 2026 includes enterprise revenue of approximately $14.71 billion to $14.83 billion and free cash flow of approximately $1.24 billion to $1.36 billion.

Against that scale, a $722 million upfront acquisition is meaningful without being transformative for the entire company.

The more consequential disclosures will arrive after closing, when investors can begin assessing the integration and commercial performance of the acquired operations.

For OPKO, the coming quarters will help clarify how management intends to use the proceeds and how much operating activity remains after the divestiture.

Investors should pay particular attention to whether the company can reduce its ongoing cash requirements as it exits substantial laboratory operations.

For Labcorp, the clearest evidence of success would be sustained revenue from the acquired business, improved profitability, and accelerating adoption of 4Kscore.

For OPKO, success would mean turning the proceeds into a stronger financial position and improved prospects for its remaining biopharmaceutical business.

Those are very different tests of the same transaction.

The Bigger Picture

The most interesting aspect of this deal is not the amount Labcorp is paying. It is the way the transaction illustrates two competing sources of value in healthcare.

One is scientific innovation: developing a diagnostic that can improve clinical decision-making.

The other is commercial infrastructure: building a system capable of delivering that diagnostic reliably, affordably, and at scale.

BioReference helped develop and establish the 4Kscore franchise. Labcorp believes it can broaden the test’s reach while incorporating additional laboratory operations into its existing network.

OPKO, meanwhile, is choosing to concentrate more of its future on pharmaceutical innovation rather than the infrastructure of laboratory testing.

Neither company is necessarily abandoning a valuable business. Each is attempting to concentrate on the activities where it believes it has the greatest advantage.

The logic is compelling, but the ultimate outcome remains uncertain.

Labcorp must demonstrate that national scale can produce more value from the acquired assets than their purchase price implies. OPKO must show that the proceeds and greater strategic focus can improve the economics of the company that remains.

For investors, that is the real significance of the agreement.

The transaction may be worth as much as $872 million, but its success will not be measured by the headline consideration. It will be measured by what the two companies accomplish after the assets change hands.

The deal is ultimately a bet that a medical test can become more valuable in the hands of the company best equipped to distribute it, while the company selling it can become more valuable by focusing on something else.

That is a much more consequential proposition than simply buying another laboratory.

---

MacroHint provides independent analysis of markets, companies, and the economic forces shaping business decisions. This article is for informational purposes only and does not constitute investment advice.